Overview

4 Week Treatment With Three Oral Doses of BI 10773 in Patients With Type 2 Diabetes

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
Primary objective: safety and tolerability of BI 10773 in male and female patients with type 2 diabetes Secondary objective: pharmacokinetics and pharmacodynamics of BI 10773
Phase:
Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Empagliflozin
Criteria
Inclusion Criteria:

- Male and postmenopausal or hysterectomised female patients with type 2 diabetes

- Age >18 and < 70 years

- BMI >18.5 and <40 kg/m2

Exclusion Criteria:

- Antidiabetic treatment with insulin or glitazones or with more than one oral
hypoglycaemic agent;

- Fasted blood glucose > 240 mg/dl (>13.3 mmol/L) or a blood glucose level above 400
mg/dl (22.2 mmol/L) postprandially;

- HbA1c > 8.5 %